(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -31.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Novavax's revenue in 2025 is $1,078,718,000.On average, 2 Wall Street analysts forecast NVAX's revenue for 2025 to be $167,483,515,566, with the lowest NVAX revenue forecast at $167,315,409,164, and the highest NVAX revenue forecast at $167,651,621,969. On average, 4 Wall Street analysts forecast NVAX's revenue for 2026 to be $88,938,357,104, with the lowest NVAX revenue forecast at $52,666,842,608, and the highest NVAX revenue forecast at $176,162,516,167.
In 2027, NVAX is forecast to generate $55,254,544,256 in revenue, with the lowest revenue forecast at $46,064,402,738 and the highest revenue forecast at $64,458,654,035.